{"nctId":"NCT00505778","briefTitle":"A Comparison of Once a Day Dose Compared to 2 Doses/Day","startDateStruct":{"date":"2007-07"},"conditions":["Ulcerative Colitis"],"count":1027,"armGroups":[{"label":"Mesalamine (Asacol) Once-Daily","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Mesalamine Once-Daily"]},{"label":"Mesalamine (Asacol) Twice-Daily","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Mesalamine Twice-Daily"]}],"interventions":[{"name":"Mesalamine Once-Daily","otherNames":["Asacol QD"]},{"name":"Mesalamine Twice-Daily","otherNames":["Asacol BID"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Documented history of ulcerative colitis that has been successfully maintained in remission for at least 3 months prior to study entry\n* At least one flare in the past 18 months\n* Utilizing a stable maintenance dose of oral Asacol of 1.6 g/day up to 2.4 g/day (stable dose is defined as the same dose for the past 3 months)\n* Females must be postmenopausal or surgically sterile or have a negative urine pregnancy test and practice acceptable contraception\n\nExclusion Criteria:\n\n* History of or current renal disease\n* History of hepatic disease\n* History of allergy or hypersensitivity to salicylates, aminosalicylates\n* Treatment with immunomodulatory therapy, biologic therapy or corticosteroids within 90 days of screening\n* Received any antidiarrheals, antispasmodics, or antibiotic within 1 month of screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Patients Remaining in Remission at Month 6, ITT Population, Determined by the Simple Clinical Colitis Activity Index (SCCAI)","description":"Remission defined as SCCAI \\<5. Simple Clinical Colitis Activity Index: minimum score 0, maximum score 19, reflects disease activity over the 24 hours prior to completion. Composite Score: bowel frequency (day, 0-3) (night, 0-2), defecation urgency (0-3), blood in stool (0-3), general well being (0-4), extracolonic features (arthritis, pyoderma gangrenosum, erythema nodosum, uveitis - 1 per manifestation).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.5","spread":null},{"groupId":"OG001","value":"91.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Remaining in Remission at Month 3, ITT Population","description":"Remission defined as SCCAI \\< 5. Simple Clinical Colitis Activity Index: minimum score 0, maximum score 19, reflects disease activity over the 24 hours prior to completion. Composite Score: bowel frequency (day, 0-3) (night, 0-2), defecation urgency (0-3), blood in stool (0-3), general well being (0-4), extracolonic features (arthritis, pyoderma gangrenosum, erythema nodosum, uveitis - 1 per manifestation).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.8","spread":null},{"groupId":"OG001","value":"95.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Remaining in Remission at Month 12, ITT Population","description":"Remission defined as SCCAI score \\< 5. Simple Clinical Colitis Activity Index: minimum score 0, maximum score 19, reflects disease activity over the 24 hours prior to completion. Composite Score: bowel frequency (day, 0-3) (night, 0-2), defecation urgency (0-3), blood in stool (0-3), general well being (0-4), extracolonic features (arthritis, pyoderma gangrenosum, erythema nodosum, uveitis - 1 per manifestation).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.4","spread":null},{"groupId":"OG001","value":"85.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Who Relapse/Flare Within 6 Months, ITT Population","description":"Relapse/flare is defined as SCCAI \\>= 5. Simple Clinical Colitis Activity Index: minimum score 0, maximum score 19, reflects disease activity over the 24 hours prior to completion. Composite Score: bowel frequency (day, 0-3) (night, 0-2), defecation urgency (0-3), blood in stool (0-3), general well being (0-4), extracolonic features (arthritis, pyoderma gangrenosum, erythema nodosum, uveitis - 1 per manifestation).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]}]},{"type":"SECONDARY","title":"Total MARS (Medication Adherence Report Scale) Questionnaire Scores, ITT Population, Month 6","description":"MARS: Composite score for the following statements: I change how many times per day I take my medicine, I forget to use it, I stop taking it for a while, I only use it when I am having active symptoms, I decide to miss out on a dose, I take less than instructed, I take more than instructed, I avoid using it if I can, I use it regularly every day (reverse scored): 5-never, 4-rarely, 3-sometimes, 2-often, 1-very often. Minimum score 9, maximum score 45.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.3","spread":"0.23"},{"groupId":"OG001","value":"41.8","spread":"0.24"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Indicating Ulcerative Colitis in Remission (Patient Defined Remission Index), ITT Population, Month 6","description":"Is your ulcerative colitis in remission (not active)? Y/N","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.1","spread":null},{"groupId":"OG001","value":"86.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":18,"n":512},"commonTop":[]}}}